Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 1/20 | 0.53 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.52 |
| ▸ | F2 | P00734 | 3/20 | 0.51 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.49 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | CCR4 | P51679 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3148367 | 1.00 | NPBWR1 (0.53) | NPBWR1MCHR1CYP1A2SPHK1F2 | |
| SCHEMBL1815987 | 1.00 | NPBWR1 (0.53) | NPBWR1MCHR1CYP1A2SPHK1F2 | |
| SCHEMBL7814225 | 0.96 | NPBWR1 (0.58) | NPBWR1MCHR1SIGMAR1CD274PDCD1 | |
| SCHEMBL7814221 | 0.96 | NPBWR1 (0.58) | NPBWR1MCHR1SIGMAR1CD274PDCD1 | |
| Hydrochloric Acid SCHEMBL7618359 | 0.95 | NPBWR1 (0.57) | NPBWR1MCHR1F2CD274PDCD1 | |
| SCHEMBL7309417 | 0.88 | SPHK1 (0.63) | NPBWR1MCHR1SPHK1F2CD274 | |
| SCHEMBL6508602 | 0.87 | MAOB (0.65) | SPHK1CD274PDCD1 | |
| SCHEMBL6508605 | 0.87 | MAOB (0.65) | SPHK1CD274PDCD1 | |
| SCHEMBL1972076 | 0.87 | CYP1A2 (0.60) | MCHR1CYP1A2SPHK1CD274PDCD1 | |
| SCHEMBL2587055 | 0.87 | CYP1A2 (0.60) | MCHR1CYP1A2SPHK1CD274PDCD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220087971-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | BACH BIOSCIENCES, LLC | 2022-03-24 | — | — | US | disclosed |
| US-10633630-B2 | Acceleration of Mycobacterium growth | ST GEORGE'S HOSPITAL MEDICAL SCHOOL (GB) | 2020-04-28 | — | — | US | disclosed |
| EP-3158053-B1 | ACCELERATION OF MYCOBACTERIUM GROWTH | ST GEORGES HOSPITAL MEDICAL SCHOOL (GB) | 2019-03-13 | — | — | EP | disclosed |
| US-10174077-B2 | Method of inhibiting activity of cell surface fibroblast activation protein alpha | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2019-01-08 | — | — | US | disclosed |
| US-10155789-B2 | Substrates and inhibitors of prolyl oligopeptidase and methods of use thereof | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2018-12-18 | — | — | US | disclosed |
| US-20170260231-A1 | Substrates and Inhibitors of Prolyl Oligopeptidase and Methods of Use Thereof | UNIV OKLAHOMA (US) | 2017-09-14 | — | — | US | disclosed |
| US-9707282-B2 | Small cationic antimicrobial peptides | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2017-07-18 | — | — | US | disclosed |
| US-9688722-B2 | Substrates and inhibitors of prolyl oligopeptidase and methods of use | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2017-06-27 | — | — | US | disclosed |
| US-20170121672-A1 | ACCELERATION OF MYCOBACTERIUM GROWTH | ST GEORGE'S HOSPITAL MEDICAL SCHOOL (GB) | 2017-05-04 | — | — | US | disclosed |
| EP-3158053-A1 | ACCELERATION OF MYCOBACTERIUM GROWTH | St. George's Hospital Medical School (GB) | 2017-04-26 | — | — | EP | disclosed |
| US-20110144037-A1 | Substrates and Inhibitors of Antiplasmin Cleaving Enzyme and Fibroblast Activation Protein and Methods of Use | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA | 2011-06-16 | — | — | US | disclosed |
| US-20100076015-A1 | Aminopyridine Derivatives | VANTIA LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
| WO-2009133348-A1 | AMINOPYRIDINE DERIVATIVES | VANTIA LIMITED (GB) | 2009-11-05 | — | — | WO | disclosed |
| CN-101512338-A | Substrates and inhibitors of antiplasmin cleaving enzyme and methods of use thereof | MCKEE PATRICK A (US) | 2009-08-19 | — | — | CN | disclosed |
| EP-2061886-A1 | SMALL CATIONIC ANTIMICROBIAL PEPTIDES | The University of British Columbia (CA) | 2009-05-27 | — | — | EP | disclosed |
| EP-2038653-A2 | SUBSTRATES AND INHIBITORS OF ANTIPLASMIN CLEAVING ENZYME AND METHODS OF USE | McKee, Patrick A. (US) | 2009-03-25 | — | — | EP | disclosed |
| WO-2008151434-A1 | SMALL CATIONIC ANTIMICROBIAL PEPTIDES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2008-12-18 | — | — | WO | disclosed |
| US-20080057491-A1 | Substrates and inhibitors of antiplasmin cleaving enzyme and methods of use | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-03-06 | — | — | US | disclosed |
| WO-2008022444-A1 | SMALL CATIONIC ANTIMICROBIAL PEPTIDES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2008-02-28 | — | — | WO | disclosed |
| WO-2007146104-A2 | SUBSTRATES AND INHIBITORS OF ANTIPLASMIN CLEAVING ENZYME AND METHODS OF USE | MCKEE PATRICK A (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076015-A1 | Aminopyridine Derivatives | CHRM1, ARG1, ARG2 | NPBWR1 941/4885MCHR1 2478/4885CYP1A2 130/4885 |
| US-20220087971-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | FAP, FIBP, GOT1 | NPBWR1 3549/4885MCHR1 4812/4885CYP1A2 2416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.